Puma Biotechnology Inc (NYSE:PBYI) is set to release its earnings data after the market closes on Thursday, November 9th. Analysts expect Puma Biotechnology to post earnings of ($2.50) per share for the quarter.

Puma Biotechnology (NYSE:PBYI) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.78). On average, analysts expect Puma Biotechnology to post $-8.83 EPS for the current fiscal year and $-4.97 EPS for the next fiscal year.

Several research analysts have weighed in on PBYI shares. Credit Suisse Group upped their price objective on shares of Puma Biotechnology from $118.00 to $136.00 and gave the company an “outperform” rating in a research note on Monday, September 11th. Leerink Swann upped their price objective on shares of Puma Biotechnology to $140.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. J P Morgan Chase & Co reiterated a “buy” rating on shares of Puma Biotechnology in a research note on Tuesday, August 1st. Stifel Nicolaus upped their price objective on shares of Puma Biotechnology from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, October 2nd. Finally, BidaskClub upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Puma Biotechnology currently has an average rating of “Buy” and a consensus price target of $126.56.

In other news, SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $100.09, for a total transaction of $1,501,350.00. Following the transaction, the senior vice president now owns 28,239 shares in the company, valued at approximately $2,826,441.51. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 22.70% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Puma Biotechnology Inc (PBYI) to Release Earnings on Thursday” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/02/puma-biotechnology-inc-pbyi-to-release-earnings-on-thursday.html.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Earnings History for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.